Technology
Health
Pharmaceutical

Aeglea BioTherapeutics

$6.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (0.74%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AGLE and other stocks, options, ETFs, and crypto commission-free!

About

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. Read More The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Employees
61
Headquarters
Austin, Texas
Founded
2013
Market Cap
196.67M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
192.22K
High Today
$6.87
Low Today
$6.61
Open Price
$6.79
Volume
35.87K
52 Week High
$12.00
52 Week Low
$6.31

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Cancer Prevention
Biotechnology
2016 IPO

News

Yahoo FinanceMay 22

Aeglea Biotherapeutics Inc President & CEO Anthony G. Quinn Bought $180,028 of Shares

- By insider President & CEO of Aeglea Biotherapeutics Inc (AGLE) Anthony G. Quinn bought 26,592 shares of AGLE on 05/22/2019 at an average price of $6.77 a share. The total cost of this purchase was $180,028. Aeglea BioTherapeutics Inc is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism, which will transform the lives of patients with inborn errors of metabolism and cancer. Aeglea BioTherapeutics Inc has a market cap of $197.610 milli...

52
Associated PressMay 7

Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights

Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from February 2019 Public Offering Extends Cash Runway Through Q1 of 2021 Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D on Track for First Patient Dosing During 2Q19 AUSTIN, Texas, May 07, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers nex...

37
Yahoo FinanceApr 27

Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?

81

Earnings

-$0.64
-$0.55
-$0.46
-$0.37
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.